Lastly, breast cancer patients with tumors expressing COMP, and undergoing chemotherapy or endocrine therapy, exhibited decreased overall survival (OS) in comparison with patients with tumors showing low COMP expression. This evidence concerns the gene COMP and breast carcinoma.